Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (926)	2/6/2002 1:04:07 PM
From: Biomaven	Respond to of 2243

The Gilboa paper is now available online. Here's the abstract: J Clin Invest, February 2002, Volume 109, Number 3, 409-417 Copyright ©2002 by the American Society for Clinical Investigation -------------------------------------------------------------------------------- Article Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors Axel Heiser1, Doris Coleman1, Jens Dannull1, Donna Yancey1, Margaret A. Maurice1, Costas D. Lallas1, Philipp Dahm1, Donna Niedzwiecki2, Eli Gilboa1,3 and Johannes Vieweg1 1 Cancer Immunotherapy Program, Division of Urology, Department of Surgery, 2 Department of Biostatistics, and 3 Experimental Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA Address correspondence to: Johannes Vieweg, Duke University Medical Center, Medical Sciences Research Building, Suite 466, Box 2626, Durham, North Carolina 27710, USA. Phone: (919) 684-9949; Fax: (919) 681-7414; E-mail: viewe001@mc.duke.edu. Received for publication October 8, 2001, and accepted in revised form November 20, 2001. Autologous dendritic cells (DCs) transfected with mRNA encoding prostate-specific antigen (PSA) are able to stimulate potent, T cell–mediated antitumor immune responses in vitro. A phase I trial was performed to evaluate this strategy for safety, feasibility, and efficacy to induce T cell responses against the self-protein PSA in patients with metastatic prostate cancer. In 13 study subjects, escalating doses of PSA mRNA–transfected DCs were administered with no evidence of dose-limiting toxicity or adverse effects, including autoimmunity. Induction of PSA-specific T cell responses was consistently detected in all patients, suggesting in vivo bioactivity of the vaccine. Vaccination was further associated with a significant decrease in the log slope PSA in six of seven subjects; three patients that could be analyzed exhibited a transient molecular clearance of circulating tumor cells. The demonstration of vaccine safety, successful in vivo induction of PSA-specific immunity, and impact on surrogate clinical endpoints provides a scientific rationale for further clinical investigation of RNA-transfected DCs in the treatment of human cancer. Full text at: jci.org and some commentary at: jci.org This would make NBSC happy were it come to pass: <g> If only 10% of the estimated 200,000 men who will develop prostate cancer in 2002 were eligible for adoptive DC immunotherapy, the incubator and freezer space required to accommodate these cells could quickly outstrip all available resources in the US.